Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

Rania Abdel-latif; Wadha Al Muftah; Shaban Mohammed; Toka AlHsson; Daoud Al-Badriyeh; Radja Badji; Awad Al-Qahtani; Abdul Rahman Arabi; Said Ismail; Moza Al Hail; Jassim Al Suwaidi

doi:10.1016/j.clinthera.2026.02.002

Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

Rania Abdel-latif^*
, Wadha Al Muftah
, Shaban Mohammed
, Toka AlHsson
, Daoud Al-Badriyeh
, Radja Badji
, Awad Al-Qahtani
, Abdul Rahman Arabi
, Said Ismail
, Moza Al Hail
, Jassim Al Suwaidi

^*Corresponding author for this work

Qatar Foundation HQ
Hamad Medical Corporation
College of Pharmacy

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	390-391
Number of pages	2
Journal	Clinical Therapeutics
Volume	48
Issue number	4
DOIs	https://doi.org/10.1016/j.clinthera.2026.02.002
Publication status	Published - Apr 2026
Externally published	Yes

Access to Document

10.1016/j.clinthera.2026.02.002

Cite this

Abdel-latif, R., Muftah, W. A., Mohammed, S., AlHsson, T., Al-Badriyeh, D., Badji, R., Al-Qahtani, A., Arabi, A. R., Ismail, S., Hail, M. A., & Suwaidi, J. A. (2026). Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives. Clinical Therapeutics, 48(4), 390-391. https://doi.org/10.1016/j.clinthera.2026.02.002

@article{0e172d228a094ba99f977ab725801e1d,

title = "Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives",

author = "Rania Abdel-latif and Muftah, \{Wadha Al\} and Shaban Mohammed and Toka AlHsson and Daoud Al-Badriyeh and Radja Badji and Awad Al-Qahtani and Arabi, \{Abdul Rahman\} and Said Ismail and Hail, \{Moza Al\} and Suwaidi, \{Jassim Al\}",

year = "2026",

month = apr,

doi = "10.1016/j.clinthera.2026.02.002",

language = "English",

volume = "48",

pages = "390--391",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Elsevier Inc.",

number = "4",

}

Abdel-latif, R, Muftah, WA, Mohammed, S, AlHsson, T, Al-Badriyeh, D, Badji, R, Al-Qahtani, A, Arabi, AR, Ismail, S, Hail, MA & Suwaidi, JA 2026, 'Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives', Clinical Therapeutics, vol. 48, no. 4, pp. 390-391. https://doi.org/10.1016/j.clinthera.2026.02.002

TY - JOUR

T1 - Response to Letter to the Editor

T2 - Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

AU - Abdel-latif, Rania

AU - Muftah, Wadha Al

AU - Mohammed, Shaban

AU - AlHsson, Toka

AU - Al-Badriyeh, Daoud

AU - Badji, Radja

AU - Al-Qahtani, Awad

AU - Arabi, Abdul Rahman

AU - Ismail, Said

AU - Hail, Moza Al

AU - Suwaidi, Jassim Al

PY - 2026/4

Y1 - 2026/4

UR - https://www.scopus.com/pages/publications/105035201528

U2 - 10.1016/j.clinthera.2026.02.002

DO - 10.1016/j.clinthera.2026.02.002

M3 - Letter

C2 - 41807153

AN - SCOPUS:105035201528

SN - 0149-2918

VL - 48

SP - 390

EP - 391

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 4

ER -

Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

Access to Document

Other files and links

Cite this